243 related articles for article (PubMed ID: 18685574)
1. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
2. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
[TBL] [Abstract][Full Text] [Related]
3. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease.
Bergner R; Diel IJ; Henrich D; Hoffmann M; Uppenkamp M
Onkologie; 2006 Nov; 29(11):534-40. PubMed ID: 17068390
[TBL] [Abstract][Full Text] [Related]
4. Renal complications from bisphosphonate treatment.
Hirschberg R
Curr Opin Support Palliat Care; 2012 Sep; 6(3):342-7. PubMed ID: 22710581
[TBL] [Abstract][Full Text] [Related]
5. The kidney and bisphosphonates.
Miller PD
Bone; 2011 Jul; 49(1):77-81. PubMed ID: 21232648
[TBL] [Abstract][Full Text] [Related]
6. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for zoledronic acid treatment of patients with bone metastases.
Berenson JR
Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
[TBL] [Abstract][Full Text] [Related]
8. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
9. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
[TBL] [Abstract][Full Text] [Related]
10. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Nagahama M; Sica DA
Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
12. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Bergner R; Siegrist B; Gretz N; Pohlmeyer-Esch G; Kränzlin B
Pharmacol Res; 2015 Sep; 99():16-22. PubMed ID: 25976681
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate nephropathy: A case series and review of the literature.
de Roij van Zuijdewijn C; van Dorp W; Florquin S; Roelofs J; Verburgh K
Br J Clin Pharmacol; 2021 Sep; 87(9):3485-3491. PubMed ID: 33595131
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity related to new therapeutic compounds.
Szeto CC; Chow KM
Ren Fail; 2005; 27(3):329-33. PubMed ID: 15957551
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
19. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
[TBL] [Abstract][Full Text] [Related]
20. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
